Universitätsklinikum Frankfurt in Germany was the first study site to be activated for the RSV vaccine effectiveness study in adults hospitalised with severe acute respiratory infection (SARI) in Europe. Other study sites will be activated in Europe and in the United Kingdom throughout the coming months.
This study will continuously monitor different marketed RSV vaccines’ effectiveness against hospitalisations due to SARI caused by RSV in older adults (EUPAS1000000035).
The European Union and United Kingdom recently granted marketing authorisation for vaccines to prevent RSV-associated lower respiratory tract disease in 1) adults aged 60 years and older and 2) newborns (through passive immunisation of newborns following vaccination of pregnant women).